European Commission Approves IMBRUVICA (ibrutinib) as the First Targeted Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Who Would Be Eligible for Autologous Stem Cell Transplant
July 24, 2025
July 24, 2025
RARITAN, New Jersey, July 24 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
European Commission approves IMBRUVICA (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
Ibrutinib is the first approved Bruton's tyrosine kinase (BTK) inhibitor . . .
* * *
European Commission approves IMBRUVICA (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
Ibrutinib is the first approved Bruton's tyrosine kinase (BTK) inhibitor . . .